David Cummings—Recommendations for Metabolic Surgery During and After the COVID-19 Pandemic
David Cummings, MD, FASMBS
11 Minutes
VIDEO 2 OF 5
Next Up
Claiming CME Credit Requirements
The learner must review all sections of the activity and complete a series of assessment questions to receive continuing education credits. Partial credits will not be issued. Completion of this activity takes approximately 2 hours.
All content is the copyrighted material of the ©2020 Cine-Med, Inc.
Hardware / Software Requirements
An internet connection speed of at least 4Mbps and a modern browser
Modern browsers have a built in PDF reader which would be necessary for you to view your completion certificates
Supported by an Educational Grant from: Medtronic
About The Program
Overview
This activity explores the varying levels of obesity. This activity covers research on mechanisms of action of metabolic surgery, their RCTs that inform the question of where such operations fit in the overall treatment algorithm for type 2 diabetes and obesity, and how new data from those RCTs has led to policy changes pertaining to surgery that are evolving based on recommendations from the Diabetes Surgery Summit (DSS-2) consensus conference.
Target Audience
This activity is designed to meet the educational needs of Primary Care Physicians and Endocrinologists who regularly are asked to treat and manage overweight and obese patients.
Activity Goal
This activity is designed to address the following core and team competencies: Patient Care and Medical Knowledge
Learning Objectives
- Discuss the weight-independent mechanisms mediating remission of type 2 diabetes after selected types of bariatric/metabolic surgery.
- Describe recent Level 1 evidence from randomized clinical trials directly comparing surgical vs. non-surgical approaches to diabetes care, including among patients with a baseline BMI <35 kg/m2.
- Identify new policy changes from the 2nd Diabetes Surgery Summit and the American Diabetes Association advocating consideration of metabolic surgery to treat patients with inadequately controlled type 2 diabetes and a BMI as low as 30 kg/m2, or 27.5 kg/m2 for Asians.
Faculty
Dana Portenier, MD
Duke University Medical Center
Changing the Conversation from Bariatric to Metabolic Surgery
David Cummings, MD, FASMBS
University of Washington, V.A. Puget Sound, Diabetes & Obesity Center of Excellence, Seattle
DSS Recommendations for Bariatric/Metabolic Surgery During and After the Covid-19 Pandemic
Kelli Friedman, PhD
Assistant Professor, Department of Psychiatry and Behavioral Sciences; Assistant Professor, Department of Surgery; Director, Psychological Services at Duke Center for Metabolic & Weight Loss Surgery
To Have Bariatric/Metabolic Surgery or Not: The Psychology Behind the Decision
Lillian Craggs-Dino, DHA, RDN, LDN, CLT
Nutrition Management for Diabesity
Deborah Horn, DO, MPH, MFOMA
Medical Director, Center for Obesity Medicine and Metabolic Performance, Assistant Professor, Department of Surgery, University of Texas McGovern Medical School
Intersection of Obesity, Diabetes, and Cardiovascular Disease
Non-Endorsement Statement
The provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty’s commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations.
– All provider employees and activity planners in control of content have indicated that they have no relevant financial relationships to disclose.
Dana Portenier, MD
Medtronic – Speaker/Research Grant; Gore – Education Grant/ Speaker; Teleflex – Consultant/Research Grant; Da Vinci -Consultant/Research Grant; Levita Magnetics – Advisory Board Changzhou Panda Medical Co. Ltd -Ownership; Novo Nordisk – Consultant
David Cummings, MD
P.I. on the COSMID trial funded by Johnson & Johnson; ARMMS-T2D Trial funded by NIH, Johnson & Johnson, and Covidien
Deborah Horn, DO
Novonordisk – Consultant, Research, Speaker; Bausch/Valeant – Consultant; Medtronic – Consultant
Kelli Friedman, PhD
Medtronic – Speaker/Research Grant; Gore – Education Grant/ Speaker; Teleflex – Consultant/Research Grant; Da Vinci Consultant/Research Grant; Levita Magnetics – Advisory Board Changzhou Panda Medical Co. Ltd -Ownership; Novo Nordisk – Consultant
Lillian Craggs-Dino, DHA, RDN, LDN, CLT: Bariatric Fusion – Advisory Board
Accreditation
In support of improving patient care, Ciné-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
Ciné-Med designates this enduring material for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity provides 2 contact hours for nurses.
All other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for activities designated for AMA PRA Category 1 Credits™, consult your professional licensing board.
Credit Tracking
Those participants wishing to claim a Certificate of Credit by completing a series of assessment questions are directed to use the following URL https://cine-med.com/certificates/diabesitymxm
Industry Support
This activity is supported by an educational grant from Medtronic
One Response